Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VISEN PharmaceuticalsFRA:T06 7 EV-to-OCF is -3.67 as of Aug. 29, 2026. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 1,006 Drug Manufacturers companies, VISEN Pharmaceuticals ranks better than 75.35% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, VISEN Pharmaceuticals's Enterprise Value is €206.81 Mil.
VISEN Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-56.36 Mil. Therefore, VISEN Pharmaceuticals's EV-to-OCF for today is -3.67.
The historical rank and industry rank for VISEN Pharmaceuticals's EV-to-OCF or its related term are showing as below:
FRA:T06'
s EV-to-OCF Range Over the Past 10 Years
Min: -6.89 Med: -4.24 Max: -2.99
Current: -3.69
During the past 4 years, the highest EV-to-OCF of VISEN Pharmaceuticals was -2.99. The lowest was -6.89. And the median was -4.24.
FRA:T06's EV-to-OCF is ranked better than 75.35% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.505
vs FRA:T06: -3.69
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VISEN Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
VISEN Pharmaceuticals's share price for today is €2.06.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.275.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, VISEN Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VISEN Pharmaceuticals EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, VISEN Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where VISEN Pharmaceuticals's EV-to-OCF falls into.
VISEN Pharmaceuticals's current Enterprise Value is €206.81 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. VISEN Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €-56.36 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VISEN Pharmaceuticals (FRA:T06) has a EV-to-OCF of -3.67 as of Aug. 29, 2026. According to the industry distribution chart, VISEN Pharmaceuticals ranks #248 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 24.7%.
Is VISEN Pharmaceuticals' EV-to-OCF too high?
VISEN Pharmaceuticals' current EV-to-OCF is -3.67. Based on the distribution chart, VISEN Pharmaceuticals ranks #248 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, VISEN Pharmaceuticals ranks #248 out of 1006 companies for EV-to-OCF. This places VISEN Pharmaceuticals in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.51, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VISEN Pharmaceuticals's current EV-to-OCF is -3.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current EV-to-OCF of -3.67. The current EV-to-OCF is -3.67. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current EV-to-OCF is -3.67 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score
Get the complete analysis for FRA:T06
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:T06 has been successfully added to your 
